Literature DB >> 20096354

Using transdermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: effect of experimental conditions and a comparison with other enhancement strategies.

Jennyfer Cázares-Delgadillo1, Adriana Ganem-Rondero, David Quintanar-Guerrero, Alicia C López-Castellano, Virginia Merino, Yogeshvar N Kalia.   

Abstract

The objectives of the study were (i) to investigate the effect of experimental parameters on the iontophoretic transport of granisetron, (ii) to identify the relative contributions of electromigration (EM) and electroosmosis (EO), (iii) to determine the feasibility of delivering therapeutic amounts of drug for the treatment of chemotherapy-induced nausea and vomiting and (iv) to test the in vitro results in a simple animal model in vivo. Preliminary in vitro studies using aqueous granisetron formulations investigating the effect of drug concentration (5, 10, 20 and 40 mM) and current density (0.1, 0.2, 0.3 mA cm(-2)) were performed using porcine ear skin. As expected, cumulative delivery in vitro at the 20 and 40 mM concentrations was significantly greater than that at 5 and 10mM, which were not statistically different (p<0.05). Increasing the applied current density from 0.1 to 0.3 mA cm(-2) resulted in a approximately 4.2-fold increase in iontophoretic flux. Furthermore, in the absence of Na(+) in the formulation, no dependence of iontophoretic flux on drug concentration was reported (at a granisetron concentration of 40 mM, the transport rate was 2.93+/-0.62 microg cm(-2)min(-1)). Co-iontophoresis of acetaminophen was used to show that EM was the predominant transport mechanism accounting for 71-86% of total granisetron delivery. In vivo studies in Wistar rats (40 mM granisetron; application of 0.3 mA cm(-2) for 5h with Ag/AgCl electrodes and salt bridges) showed an average iontophoretic input rate (k(input)) of 0.83+/-0.26 microg min(-1) and a maximum plasma concentration (C(max)) of 0.092+/-0.004 microg ml(-1). Based on these results and given the known pharmacokinetics, transdermal iontophoresis could achieve therapeutic drug levels for the management of chemotherapy-induced emesis using a reasonably sized (4-6 cm(2)) patch. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096354     DOI: 10.1016/j.ejps.2010.01.008

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  4 in total

1.  Preparation and characterization of niosomal gel for iontophoresis mediated transdermal delivery of isosorbide dinitrate.

Authors:  Sanyog Jain; Bankim H Chaudhari; Nitin K Swarnakar
Journal:  Drug Deliv Transl Res       Date:  2011-08       Impact factor: 4.617

2.  Transdermal iontophoresis delivery system for terazosin hydrochloride: an in vitro and in vivo study.

Authors:  Changzhao Jiang; Xiumei Jiang; Xiumin Wang; Jiaxu Shen; Mengjie Zhang; Leilei Jiang; Rui Ma; Tingting Gan; Yingbiao Gong; Jincui Ye; Wenyan Gao
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

3.  Biophysical assessment of DC iontophoresis and current density on transdermal permeation of methotrexate.

Authors:  Rachna Prasad; Sneh Anand; Veena Koul
Journal:  Int J Pharm Investig       Date:  2011-10

4.  Enhancement strategies for transdermal drug delivery systems: current trends and applications.

Authors:  Delly Ramadon; Maeliosa T C McCrudden; Aaron J Courtenay; Ryan F Donnelly
Journal:  Drug Deliv Transl Res       Date:  2021-01-20       Impact factor: 4.617

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.